EVP, Chief Commercial Officer - Specialty · Amneal Pharmaceuticals, Inc. (AMRX)

Joseph Todisco

FY2020 is the first fiscal year CompBrief holds for Joseph Todisco as a named executive officer of Amneal Pharmaceuticals; the record below is that year, complete. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2020

$1,671,129

Salary $458,539Stock awards $881,006

6th of 7 named executive officers at Amneal Pharmaceuticals by FY2020 total.

7 named officers on file for Amneal Pharmaceuticals, FY2020

Joseph Todisco’s pay file — $29

  • 1 fiscal year of pay, line by line
  • 2 equity grants, each cited to its filing
  • AMRX’s disclosed peer group of 14 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Amneal Pharmaceuticals’s whole pay program stands against its peers

  • Amneal Pharmaceuticals’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on AMRX→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed March 24, 2021 (DEF 14A).

Free

Get Joseph Todisco’s full pay file as a PDF — free

More than this page: up to 10 years of Joseph’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

Joseph Todisco compensation by year

Amneal Pharmaceuticals Summary Compensation Table · the one fiscal year held
In US dollars, as Amneal Pharmaceuticals reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2020
Salary$458,539
Bonus$0
Stock awards$881,006
Option awards$0
Non-equity incentive$315,153
Pension and deferred compensation$0
All other$16,431
Total$1,671,129

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Amneal Pharmaceuticals, Inc. DEF 14A filed March 24, 2021, accession 0001308179-21-000093, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Amneal Pharmaceuticals, Inc. filed document, accession 0001308179-21-000093. Every figure is read from that document and cited to the page and table it appears in. Filed March 24, 2021.

Equity holdings

unvested awards at FY2020 year-end
TypeUnvested unitsValue at year-endExercise price
RSU118,734$542,614—
PSU59,367$271,307—
RSU33,333$152,332—
PSU22,222$101,555—
RSU8,883$40,595—
Option36,331—$2.75
Option67,874—$2.75

Per the Outstanding Equity Awards at Fiscal Year-End table in Amneal Pharmaceuticals, Inc.'s FY2020 proxy; value at the fiscal year-end close, as the company printed it.

Amneal Pharmaceuticals’s named executive officers, FY2020

as the company reported each
Named executive officerRoleFY2020 total
Anastasios KonidarisEVP & Chief Financial Officer$2,508,499
Andrew BoyerEVP, Chief Commercial Officer - Generics$2,386,531
Chintu PatelCo-Chief Executive Officer$2,328,528
Chirag PatelPresident & Co-Chief Executive Officer$2,320,716
Nikita ShahEVP, CHRO & Strategic Planning Officer$1,777,720
Joseph Todisco · this pageEVP, Chief Commercial Officer - Specialty$1,671,129
Todd BranningFormer SVP & CFO$1,270,412

The full Amneal Pharmaceuticals compensation record

free company brief

This page is one person within Amneal Pharmaceuticals's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the Amneal Pharmaceuticals proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Amneal Pharmaceuticals's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Joseph Todisco's compensation dossier · One-time report. No refunds.